Hims & Hers Health (NYSE:HIMS) Stock Price Down 4.5% - Should You Sell?

Hims & Hers Health, Inc. (NYSE:HIMS - Get Free Report) traded down 4.5% during mid-day trading on Thursday . The stock traded as low as $51.20 and last traded at $55.40. 23,154,938 shares changed hands during mid-day trading, a decline of 24% from the average session volume of 30,271,439 shares. The stock had previously closed at $58.00.

Analyst Ratings Changes

HIMS has been the topic of several recent research reports. Morgan Stanley decreased their target price on shares of Hims & Hers Health from $60.00 to $40.00 and set an "equal weight" rating on the stock in a research report on Tuesday, April 29th. TD Cowen lowered shares of Hims & Hers Health from a "buy" rating to a "hold" rating and decreased their target price for the company from $44.00 to $30.00 in a research report on Tuesday, April 29th. Needham & Company LLC reiterated a "buy" rating and set a $61.00 target price on shares of Hims & Hers Health in a research report on Tuesday, May 6th. Canaccord Genuity Group lifted their target price on shares of Hims & Hers Health from $38.00 to $68.00 and gave the company a "buy" rating in a research report on Wednesday, February 19th. Finally, Truist Financial decreased their target price on shares of Hims & Hers Health from $39.00 to $33.00 and set a "hold" rating on the stock in a research report on Thursday, April 10th. Two equities research analysts have rated the stock with a sell rating, eight have given a hold rating and four have assigned a buy rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of "Hold" and an average target price of $37.67.

Hims & Hers Health Price Performance

The company has a market capitalization of $12.29 billion, a P/E ratio of 124.75 and a beta of 1.84. The stock's 50 day simple moving average is $37.95 and its two-hundred day simple moving average is $35.08.

Hims & Hers Health (NYSE:HIMS - Get Free Report) last posted its quarterly earnings results on Monday, May 5th. The company reported $0.20 earnings per share for the quarter, topping analysts' consensus estimates of $0.12 by $0.08. The business had revenue of $586.01 million during the quarter, compared to the consensus estimate of $535.21 million. Hims & Hers Health had a net margin of 8.19% and a return on equity of 10.97%. Hims & Hers Health's revenue for the quarter was up 110.7% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.05 earnings per share. As a group, equities research analysts expect that Hims & Hers Health, Inc. will post 0.29 earnings per share for the current year.

Insider Transactions at Hims & Hers Health

In related news, insider Irene Becklund sold 2,203 shares of the stock in a transaction on Thursday, April 3rd. The shares were sold at an average price of $28.78, for a total transaction of $63,402.34. Following the completion of the transaction, the insider now owns 8,007 shares in the company, valued at approximately $230,441.46. This represents a 21.58% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO Andrew Dudum sold 128,127 shares of the stock in a transaction on Monday, March 17th. The shares were sold at an average price of $33.98, for a total transaction of $4,353,755.46. Following the completion of the sale, the chief executive officer now owns 173,655 shares of the company's stock, valued at approximately $5,900,796.90. This represents a 42.46% decrease in their position. The disclosure for this sale can be found here. Insiders sold 618,936 shares of company stock valued at $25,182,692 over the last quarter. Corporate insiders own 13.71% of the company's stock.

Institutional Trading of Hims & Hers Health

A number of large investors have recently added to or reduced their stakes in the company. Kilter Group LLC raised its position in shares of Hims & Hers Health by 1.0% in the first quarter. Kilter Group LLC now owns 43,989 shares of the company's stock valued at $1,300,000 after purchasing an additional 450 shares during the period. Geneos Wealth Management Inc. acquired a new stake in shares of Hims & Hers Health during the 1st quarter worth about $30,000. Intech Investment Management LLC lifted its stake in shares of Hims & Hers Health by 74.5% during the 1st quarter. Intech Investment Management LLC now owns 143,287 shares of the company's stock worth $4,234,000 after buying an additional 61,195 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its stake in shares of Hims & Hers Health by 23.1% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 418,699 shares of the company's stock worth $12,373,000 after buying an additional 78,543 shares during the last quarter. Finally, Arete Wealth Advisors LLC acquired a new stake in shares of Hims & Hers Health during the 1st quarter worth about $300,000. Institutional investors and hedge funds own 63.52% of the company's stock.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.